How to Make Sense of the AstraZeneca Vaccine Data Drama

U.S. health officials raise concerns about the company’s latest efficacy data

Photo: Svetlana Ustinov/Getty

“If you look at it, the data really are quite good. But when they put it into the press release, it wasn’t completely accurate.”

In its response on Tuesday, AstraZeneca said that the numbers in its March 22 press release were based on an interim analysis with a cutoff date of February 17. The company said it will immediately be in touch with the monitoring board and plans to issue results containing more recent data in 48 hours.

Former staff writer at Medium, where I covered biotech, genetics, and Covid-19 for OneZero, Future Human, Elemental, and the Coronavirus Blog.